Comparison 1. Clindamycin plus aminoglycoside versus any other regimen.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment failure	20		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Lincosamides versus cephalosporins	8	872	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.49, 0.99]
1.2 Lincosamides versus monobactams	2	181	Risk Ratio (M‐H, Fixed, 95% CI)	2.25 [0.60, 8.43]
1.3 Lincosamides versus penicillins	7	689	Risk Ratio (M‐H, Fixed, 95% CI)	0.65 [0.46, 0.90]
1.4 Lincosamides versus quinolone	3	176	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.38, 1.37]
2 Severe complication	12		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Lincosamides versus cephalosporins	4	476	Risk Ratio (M‐H, Fixed, 95% CI)	2.40 [0.30, 19.19]
2.2 Lincosamides versus monobactams	1	62	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Lincosamides versus penicillins	5	422	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.09, 1.18]
2.4 Lincosamides versus quinolone	2	160	Risk Ratio (M‐H, Fixed, 95% CI)	2.89 [0.31, 27.20]
3 Wound infection	9		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 Lincosamides versus cephalosporins	4	500	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.30, 0.93]
3.2 Lincosamides versus monobactams	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.06, 14.85]
3.3 Lincosamides versus penicillins	3	339	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.21, 1.00]
3.4 Lincosamides versus quinolone	1	97	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.05, 5.45]
4 Allergic reaction	12		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Lincosamides versus cephalosporins	6	680	Risk Ratio (M‐H, Fixed, 95% CI)	1.36 [0.44, 4.21]
4.2 Lincosamides versus monobactams	2	181	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.08, 4.31]
4.3 Lincosamides versus penicillins	2	247	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.14, 6.96]
4.4 Lincosamides versus quinolone	2	160	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.06, 13.90]
5 Diarrhea	13		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Lincosamides versus cephalosporins	7	758	Risk Ratio (M‐H, Fixed, 95% CI)	2.09 [0.77, 5.63]
5.2 Lincosamides versus monobactams	1	119	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.04, 5.10]
5.3 Lincosamides versus penicillins	4	375	Risk Ratio (M‐H, Fixed, 95% CI)	1.43 [0.55, 3.72]
5.4 Lincosamides versus quinolone	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.06, 13.90]
6 Length of stay	5		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 Lincosamides versus cephalosporins	4	494	Mean Difference (IV, Fixed, 95% CI)	‐0.26 [‐0.56, 0.04]
6.2 Lincosamides versus monobactams	1	119	Mean Difference (IV, Fixed, 95% CI)	0.45 [‐0.25, 1.15]
7 Treatment failure despite administration of prophylactic antibiotics for cesarean	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7.1 Lincosamides versus penicillins	2	229	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.63, 1.98]